This review demonstrates the application of Quality by Design principles to optimize ondansetron formulations for children, highlighting critical quality attributes and safety considerations.
Ondansetron, a foundational 5-HT3 receptor antagonist, plays a crucial role in managing chemotherapy-induced, post-operative, and acute gastroenteritis-related vomiting in children. Despite its widespread use, significant challenges persist, notably the absence of established safety and efficacy data for children younger than four years. Furthermore, marked age-dependent pharmacokinetic (PK) variability, characterized by reduced drug clearance in neonates, mandates flexible, weight-based dosing to prevent overexposure. This review applies the Quality by Design (QbD) framework (ICH Q8(R2)) to develop age-appropriate ondansetron formulations (ODF or oral solution), establishing the Quality Target Product Profile (QTPP), Critical Quality Attributes (CQAs), and Control Strategy (ICH Q10). Through proactive Quality Risk Management (QRM) and Failure Mode and Effects Analysis (FMEA), it ensures the product’s safety, efficacy, and lifecycle quality control.
No takes yet. Share an insight, caveat, or question.
Musale et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: